Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ICEL

(ICEL) (ICEL) Stock Price, News & Analysis

(ICEL) logo

About (ICEL) Stock (NASDAQ:ICEL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
264,387 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company's products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.

Receive ICEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (ICEL) and its competitors with MarketBeat's FREE daily newsletter.

ICEL Stock News Headlines

Erdemli, İçel, Türkiye
The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
See More Headlines

ICEL Stock Analysis - Frequently Asked Questions

(ICEL) (NASDAQ:ICEL) released its earnings results on Thursday, March, 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.08. The firm had revenue of $6.60 million for the quarter, compared to the consensus estimate of $5 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that (ICEL) investors own include Bank of America (BAC), Bristol Myers Squibb (BMY), Avid Bioservices (CDMO), Clovis Oncology (CLVS), Corcept Therapeutics (CORT), CRISPR Therapeutics (CRSP) and CTI BioPharma (CTIC).

Company Calendar

Last Earnings
3/05/2015
Today
6/21/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:ICEL
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:ICEL) was last updated on 6/21/2025 by MarketBeat.com Staff
From Our Partners